Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MEIS2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MEIS2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MEIS2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MEIS2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MEIS2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MEIS2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MEIS2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004563719 | Prostate | Tumor | regulation of myeloid cell differentiation | 67/3246 | 210/18723 | 1.71e-07 | 4.25e-06 | 67 |
GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
GO:000734613 | Prostate | Tumor | regulation of mitotic cell cycle | 113/3246 | 457/18723 | 3.37e-05 | 3.96e-04 | 113 |
GO:000961214 | Prostate | Tumor | response to mechanical stimulus | 60/3246 | 216/18723 | 8.45e-05 | 8.46e-04 | 60 |
GO:004578714 | Prostate | Tumor | positive regulation of cell cycle | 81/3246 | 313/18723 | 8.45e-05 | 8.46e-04 | 81 |
GO:000931415 | Prostate | Tumor | response to radiation | 109/3246 | 456/18723 | 1.94e-04 | 1.70e-03 | 109 |
GO:004593114 | Prostate | Tumor | positive regulation of mitotic cell cycle | 37/3246 | 121/18723 | 2.42e-04 | 2.05e-03 | 37 |
GO:00456381 | Prostate | Tumor | negative regulation of myeloid cell differentiation | 26/3246 | 90/18723 | 4.54e-03 | 2.24e-02 | 26 |
GO:00508901 | Prostate | Tumor | cognition | 69/3246 | 296/18723 | 5.03e-03 | 2.45e-02 | 69 |
GO:00016541 | Prostate | Tumor | eye development | 82/3246 | 371/18723 | 1.02e-02 | 4.27e-02 | 82 |
GO:19037066 | Stomach | GC | regulation of hemopoiesis | 42/1159 | 367/18723 | 9.03e-05 | 1.87e-03 | 42 |
GO:00456376 | Stomach | GC | regulation of myeloid cell differentiation | 28/1159 | 210/18723 | 1.04e-04 | 2.05e-03 | 28 |
GO:0009314 | Stomach | GC | response to radiation | 47/1159 | 456/18723 | 4.21e-04 | 6.33e-03 | 47 |
GO:00300996 | Stomach | GC | myeloid cell differentiation | 39/1159 | 381/18723 | 1.42e-03 | 1.55e-02 | 39 |
GO:004563711 | Stomach | CAG with IM | regulation of myeloid cell differentiation | 28/1050 | 210/18723 | 1.84e-05 | 5.64e-04 | 28 |
GO:190370611 | Stomach | CAG with IM | regulation of hemopoiesis | 41/1050 | 367/18723 | 2.08e-05 | 6.09e-04 | 41 |
GO:003009911 | Stomach | CAG with IM | myeloid cell differentiation | 39/1050 | 381/18723 | 2.14e-04 | 3.94e-03 | 39 |
GO:00093141 | Stomach | CAG with IM | response to radiation | 44/1050 | 456/18723 | 3.24e-04 | 5.39e-03 | 44 |
GO:0009612 | Stomach | CAG with IM | response to mechanical stimulus | 22/1050 | 216/18723 | 5.04e-03 | 4.05e-02 | 22 |
GO:00456372 | Stomach | CSG | regulation of myeloid cell differentiation | 28/1034 | 210/18723 | 1.39e-05 | 4.52e-04 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEIS2 | SNV | Missense_Mutation | | c.91C>T | p.Arg31Trp | p.R31W | O14770 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MEIS2 | SNV | Missense_Mutation | | c.1246N>T | p.Pro416Ser | p.P416S | O14770 | protein_coding | tolerated_low_confidence(0.27) | benign(0.003) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
MEIS2 | SNV | Missense_Mutation | | c.211N>A | p.Asp71Asn | p.D71N | O14770 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
MEIS2 | SNV | Missense_Mutation | | c.245N>A | p.Gly82Glu | p.G82E | O14770 | protein_coding | deleterious(0.04) | possibly_damaging(0.901) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MEIS2 | insertion | In_Frame_Ins | novel | c.644_645insATT | p.Pro215_Ser216insPhe | p.P215_S216insF | O14770 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MEIS2 | deletion | Frame_Shift_Del | | c.1216_1232delNNNNNNNNNNNNNNNNN | p.Ser406AspfsTer69 | p.S406Dfs*69 | O14770 | protein_coding | | | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MEIS2 | SNV | Missense_Mutation | rs571091781 | c.580N>A | p.Gly194Ser | p.G194S | O14770 | protein_coding | tolerated(0.12) | benign(0.164) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MEIS2 | SNV | Missense_Mutation | novel | c.214N>A | p.Ala72Thr | p.A72T | O14770 | protein_coding | tolerated(0.09) | benign(0.148) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MEIS2 | SNV | Missense_Mutation | rs770033702 | c.617N>T | p.Ser206Phe | p.S206F | O14770 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MEIS2 | SNV | Missense_Mutation | | c.248N>C | p.His83Pro | p.H83P | O14770 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |